Aktie A2JJ69 MOLECURE S.A.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Molecure S.A.

Aktien

A2JJ69

PLONCTH00011

MOC

Verzögert Warsaw S.E.
Andere Börsenplätze
 16:01:46 27.06.2024 		% 5 Tage % 1. Jan.
13,74 PLN -0,58 % Intraday Chart für Molecure S.A. -1,43 % -29,54 %
21.05. Molecure S.A. erhält die Genehmigung zur Durchführung einer klinischen Phase II-Studie (KITE) für OATD-01 zur Behandlung von Lungensarkoidose in ausgewählten Ländern der Europäischen Union und Norwegen CI
17.05. Molecure S.A. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01
Molecure S.A. announced that it has received PLN 49.968 million in funding
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Poland's Molecure Doses First Patient in Cancer Treatment Trial
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer
Molecure S.A. Announces Management Changes
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JJ69 Aktie
  4. Nachrichten Molecure S.A.
  5. Andere Sprachen